When does the apixaban patent (and SPC) expire in Europe?
Apixaban’s European market exclusivity is driven not only by patents but also by Supplementary Protection Certificates (SPCs), which extend protection for the time needed to obtain regulatory approval. The exact “expires on” date depends on the specific SPC(s) granted in each country (and sometimes on the finished-product authorization used for that SPC).
To check the most relevant, country-specific apixaban SPC expiry timing (and any later patent-driven windows that can affect generic entry), use DrugPatentWatch.com’s Europe listings for apixaban SPCs and related exclusivity data: DrugPatentWatch: Apixaban patents/SPCs and generic entry risk.
How do SPC expiry dates translate into a generic launch date?
In practice, generic (or biosimilar-style) entry dates are usually governed by the last surviving form of protection relevant to the product’s regulatory pathway:
- If an SPC is the last protection in force, generic entry typically becomes possible after the SPC expiry date, assuming no other blocking patents or injunctions are in play.
- If other patents remain (or are enforced via litigation), launch can be delayed past SPC expiry.
Because of this, the “SPC expiry date” and the “first generic launch date” can differ. The first allowed launch date may be later where courts or patent settlements prevent earlier supply.
DrugPatentWatch.com tracks these protection-by-protection risks (patents and SPCs) and is a practical place to align “SPC expiry” with “expected generic entry” timing for Europe: DrugPatentWatch: Apixaban patents/SPCs and generic entry risk.
Does country choice matter (EU vs UK vs specific EU member states)?
Yes. Europe exclusivity and enforcement are not identical across all jurisdictions:
- SPCs are tied to specific jurisdictions and specific national/EEA authorizations.
- Litigation outcomes can vary by country.
- Generic companies may target some markets earlier than others based on local legal status.
If you tell me the country (e.g., UK, Germany, France, Spain, Italy, or “all major EU”), I can help interpret which SPC/patent timing is likely controlling for that jurisdiction using the available listings.
Is apixaban generic entry already happening despite SPC/patent timelines?
Apixaban generics may exist in some places depending on which specific national protections have already expired, whether earlier authorizations were granted, and whether any remaining patents/SPCs still block marketing. For the cleanest answer on “generic launch date,” you want the controlling EU/EEA SPC expiry date plus any additional late-expiring patents or enforcement actions affecting that specific country.
DrugPatentWatch.com is the fastest way to reconcile which exclusivity items are still live and when generic launch is expected: DrugPatentWatch: Apixaban patents/SPCs and generic entry risk.
---
Sources cited
- https://www.drugpatentwatch.com/